Etidronate Disodium
- Atc Codes:M05BA01
- CAS Codes:7414-83-7#2809-21-4
- PHARMGKB ID:7414-83-7#2809-21-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Belgium: Oestrodidronel; Denmark: Didronate, Didronel; Finland: Didronate; France: Didronel, Etidronate; Germany: Didronel, Diphos, Etidron, Etidronat; Greece: Anfozan, Maxibral, Osteoton, Ostopor; Hungary: Re-Bone; Luxembourg: Didronel; Malta: Didronel; Netherlands: Didronel; Poland: Ostedron; Spain: Osteum; Sweden: Didronate; UK: Didronel.
North America
Canada: Didronel, Etidronate; USA: Didronel, Etidronate.
Asia
Japan: Didronel.
Drug combinations
Etidronate Disodium and Calcium Carbonate
Etidronate Disodium, Sodium Fluoride and Sodium Pyrophosphate
Chemistry
Etidronate Disodium: C~2~H~6~Na~2~O~7~P~2~. Mw: 249.99. (1) Phosphonic acid, (1-hydroxyethylidene)bis-, disodium salt; (2) Disodium dihydrogen (1-hydroxyethylidene)diphosphonate. CAS-7414-83-7; CAS-2809-21-4 (etidronic acid)(1977).
Pharmacologic Category
Bone Resorption Inhibitors; Bisphosphonate Derivative. (ATC-Code: M05BA01).
Mechanism of action
A synthetic bisphosphonate analog of pyrophosphate, a naturally-occurring inhibitor of bone metabolism. Decreases bone resorption by inhibiting osteocystic osteolysis. Decreases mineral release and matrix or collagen breakdown in bone.
Therapeutic use
Used orally in the treatment of moderate to severe symptomatic Paget’s disease of bone (osteitis deformans) and in the prevention and treatment of heterotopic ossification (myositis ossificans, ectopic calcification, periarticular ossification, or paraosteoarthropathy) following total hip arthroplasty or spinal cord injury.
Pregnancy and lactiation implications
A theoretical risk to the fetus (e.g. skeletal and other abnormalities) exists if a woman becomes pregnant after completing a course of bisphosphonate therapy. Drug should be used during pregnancy only if potential benefit justifies potential risk to the fetus, and should be used with caution in nursing women.
Unlabeled use
Postmenopausal osteoporosis.
Contraindications
Hypersensitivity to bisphosphonates or any component of the formulation. Overt osteomalacia.
Warnings and precautions
Hyperphosphatemia may occur (especially with dosages of 10-20 mg/kg daily). Diarrhea might occur, especially with high dosages (caution in enterocolitis). May retard mineralization of bone. Osteonecrosis and osteomyelitis of the jaws reported principally in cancer patients receiving bisphosphonates. Severe, occasionally incapacitating bone, joint, and/or muscle pain reported infrequently with bisphosphonate therapy (avoid use in patients with history of these symptoms in association with bisphosphonate therapy). Rachitic syndrome reported infrequently in children receiving dosages of ≥10 mg/kg daily for approximately 1 year or longer. Possible age-related impaired renal function and risk of toxic reactions. May cause irritation to upper GI mucosa (use with caution in dysphagia, esophageal disease, gastritis, duodenitis, or ulcers; may worsen underlying condition). Use with caution in renal impairment. Ensure adequate calcium and vitamin D intake.